Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database
Clinical Endocrinology Oct 11, 2019
Lopez DS, Huang D, Tsilidis KK, et al. - In a large, nationally representative, commercially insured cohort, researchers explored the connection of prostate cancer (PCa) with testosterone therapy [TTh] (injection or gel) and different TTh doses, and ascertained if this connection varies by the presence of diabetes at baseline. Participants in the study were 189,491 men (aged 40 to 60 years) in the IBM MarketScan Commercial Database, which involved 1,424 patients with diagnosed PCa from 2011 to 2014. To compute HRs for patients with incident PCa, multivariable adjusted Cox proportional hazards models were used. The data presented in this work showed a 33% decreased association of PCa after comparing the highest category (> 12) of TTh injections with the lowest (1-2 injections) category. Overall, increased use of TTh is inversely linked to PCa, and only among nondiabetics, this remained important. These findings support further study to infer any health advantage from TTh in large, randomized, placebo-controlled trials.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins